Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
IGIntelGenx Technologies Corp. logo

IntelGenx Technologies Corp. (IGXT)

Other OTC · Currency in USD
$0.17 ▲ +0.00 (+0.00%)
At close: May 27, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.17
Open
$0.16
Day's Range
$0.16 – $0.17
52 Week Range
$0.16 – $0.17
Volume
37,230
Avg. Volume
17,561
Market Cap
$29.69M
Beta (5Y Monthly)
2.21
PE Ratio (TTM)
--
EPS (TTM)
-$0.06
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: IntelGenx Technologies Corp.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
48
CEO
Tommy Kenny

IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry. Their current portfolio features several oral film formulations: INT0008/2008, a Rizatriptan product addressing migraine headaches; INT0046/2018, intended for adult applications; INT0007/2006, developed for the treatment of erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder; and INT0048/2020, catering to animal health. Furthermore, IntelGenx is advancing additional projects in its development pipeline, specifically INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020.

Earnings

DateEst.Actual
May 15, 2024–-$0.02
Mar 21, 2024–-$0.02
Nov 9, 2023–-$0.01
Aug 14, 2023–-$0.02
May 11, 2023–-$0.02
Mar 29, 2023–-$0.02

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Similar stocks

Get free alerts on IGXT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.